CTLA4 and non-small cell lung carcinoma: SIB003, lorigerlimab (MGD019), and vudalimab (XmAb20717) are other bispecific antibodies that target PD-1/CTLA4, and which are under investigation in phase I and II studies in solid cancer malignancies, including NSCLC patients [114,115,116].